EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

The Glasgow Prognostic Score Predicts Outcomes of Pembrolizumab or Atezolizumab Monotherapy in Patients with Pretreated Non-Small Cell Lung Cancer

Masashi Kasajima, Satoshi Igawa, Hiroya Manaka, Kaori Yamada, Yuki Akazawa, Hideaki Manabe, Yuri Yagami, Hiroki Yamamoto, Hiroki Ito, Nobuki Kaizuka, Yoshiro Nakahara, Takashi Sato und 5 weitere

Oncology · 2023 · 101 (1) · 69-76

DOI: 10.1159/000526964 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Oncology, online erschienen am 14.09.2022. Verfasst von Masashi Kasajima und 16 weiteren Autor:innen. Beteiligte Einrichtung: Department of Respiratory Medicine, Kitasato University School of Medicine, Sagamihara, Japan. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms. Die Arbeit wurde bisher 6-mal zitiert (Crossref). Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Predictors of the effectiveness of immune checkpoint inhibitor (ICI) monotherapy in previously treated patients with non-small cell lung cancer (NSCLC) remain ill-defined. We investigated whether the Glasgow prognostic score (GPS) could serve as such predictors.

Methods

Eighty patients treated with pembrolizumab or atezolizumab monotherapy as second- or subsequent-line therapy for NSCLC were retrospectively reviewed, and the associations between GPS, body mass index (BMI), and each of progression-free survival (PFS) and overall survival (OS) were assessed.

Results

The median follow-up period was 11.1 months. Patients with a BMI ≥20.4 kg/m2 had significantly longer PFS and OS (3.7 and 22.2 month, respectively) than did those with a BMI

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsHumansPrognosisRetrospective StudiesAntibodies, Monoclonal, Humanized

Stichwörter der Autor:innen

AtezolizumabGlasgow prognostic scoreNon-small cell lung cancerPembrolizumab

Substanzen

pembrolizumabAntibodies, Monoclonal, Humanizedatezolizumab

Autor:innen und Institutionen

  • Department of Respiratory Medicine, Kitasato University School of Medicine, Sagamihara, Japan.
  • School of Nursing, Kitasato University, Sagamihara, Japan.
  • School of Allied Health Sciences, Kitasato University, Sagamihara, Japan.
  • Research and Development Center for New Medical Frontiers, Kitasato University School of Medicine, Sagamihara, Japan.

Zitieren

APA

Kasajima, M., Igawa, S., Manaka, H., Yamada, K., Akazawa, Y., Manabe, H., Yagami, Y., Yamamoto, H., Ito, H., Kaizuka, N., Nakahara, Y., Sato, T., Mitshufuji, H., Yokoba, M., Kubota, M., Sasaki, J., & Naoki, K. (2023). The Glasgow Prognostic Score Predicts Outcomes of Pembrolizumab or Atezolizumab Monotherapy in Patients with Pretreated Non-Small Cell Lung Cancer. Oncology, 101(1), 69-76. https://doi.org/10.1159/000526964

Vancouver

Kasajima M, Igawa S, Manaka H, Yamada K, Akazawa Y, Manabe H, et al. The Glasgow Prognostic Score Predicts Outcomes of Pembrolizumab or Atezolizumab Monotherapy in Patients with Pretreated Non-Small Cell Lung Cancer. Oncology. 2023;101(1):69-76. doi:10.1159/000526964

BibTeX
@article{Kasajima2023,
  author = {Kasajima, Masashi and Igawa, Satoshi and Manaka, Hiroya and Yamada, Kaori and Akazawa, Yuki and Manabe, Hideaki and Yagami, Yuri and Yamamoto, Hiroki and Ito, Hiroki and Kaizuka, Nobuki and Nakahara, Yoshiro and Sato, Takashi and Mitshufuji, Hisashi and Yokoba, Masanori and Kubota, Masaru and Sasaki, Jiichiro and Naoki, Katsuhiko},
  title = {The Glasgow Prognostic Score Predicts Outcomes of Pembrolizumab or Atezolizumab Monotherapy in Patients with Pretreated Non-Small Cell Lung Cancer},
  journal = {Oncology},
  year = {2023},
  volume = {101},
  number = {1},
  pages = {69--76},
  doi = {10.1159/000526964}
}
Kostenlos starten →